Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a volatile pharmaceutical market. The transaction, involving 700 million shares priced at 357 pence each,

Pfizer has reduced its stake in the British healthcare company Haleon PLC to 7.3% by selling £2.5 billion ($3 billion) worth of shares, according to a bookrunner for the sale. J.P. Morgan Securities PLC reported Wednesday that Pfizer Inc.

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.